tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tonix Pharmaceuticals provides update on developmeny of TNX-801

Tonix Pharmaceuticals has reiterated its commitment to advance development of its live attenuated virus vaccine, TNX-801, for preventing mpox and other infectious diseases. On August 14, 2024, the World Health Organization, WHO, determined that the upsurge of mpox in a growing number of countries in Africa constitutes a public health emergency of international concern, the second such declaration in the past two years called in response to an mpox outbreak. The current outbreak was caused by Clade 1 monkeypox virus, while the 2022 outbreak was Clade 2 monkeypox virus. Tonix’s live virus vaccine candidate, TNX-801, is designed to provide long-term protection from mpox and smallpox with one dose. TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with intratracheal monkeypox virus.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1